Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
The Qatar Investment Authority has backed a new $200 million fund by Shorooq Partners, aiming to inject institutional capital into the region's mature startups and bridge a critical funding hurdle on the path to public listings.
Qatar has tripled its flagship venture capital fund to $3 billion, adding a strategic sweetener: subsidized access to AI computing power. The move aims to position Doha as a competitive hub for tech talent and deep-tech startups in the Gulf region.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Amidst a cautious market climate, companies with substantial insider ownership often signal strong internal conviction. We examine three such firms—spanning South Korean tourism, Chinese sensors, and Taiwanese biopharma—where executives and directors have significant skin in the game.
Singapore will establish its National Space Agency on April 1st, aiming to leverage its technological prowess to secure a strategic position in the rapidly expanding global space economy, as global investments continue to soar.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
At a Singapore aviation conference, FAA Administrator Bryan Bedford publicly accepted the NTSB's findings that agency failures contributed to a mid-air collision that claimed 67 lives, vowing to implement safety reforms.
Newly released documents from the Jeffrey Epstein case detail his repeated interactions with Vladimir Putin and Russian intelligence, raising serious questions about whether the financier's sex trafficking network doubled as a foreign kompromat operation.
Tens of thousands gathered in Prague's Wenceslas Square on Sunday, voicing support for President Petr Pavel in his escalating constitutional dispute with Prime Minister Andrej Babiš's coalition government. The protest, organized by pro-democracy activists, highlights deep divisions over Ukraine policy and a controversial ministerial appointment.
Columbia Sportswear is set to report its fourth-quarter earnings after the bell Tuesday, with Wall Street anticipating a year-over-year sales decline. The outerwear giant's results will be closely watched for signs of consumer resilience and its outlook in a volatile market.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.
Galderma Group's (SWX:GALD) shares have faced significant pressure in recent months, contrasting sharply with its strong yearly performance. This analysis delves into whether the current valuation presents a genuine entry point or reflects deeper concerns about the dermatology giant's ambitious growth narrative.
Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.
Intuit expands its ecosystem with a dual-pronged strategy, launching a career development program for accounting students while integrating Checkr's background check services directly into its payroll and enterprise platforms, aiming to solidify its role from talent cultivation to HR operations.
As Silver Storm Mining prepares to take the stage at the Vancouver Resource Investment Conference, investors are weighing its staggering 174% three-month surge against a premium valuation and no revenue. The spotlight is on CEO Gregory McKenzie to convince the market the story is worth the price.
Analyst firm Clear Street has raised its price target for Critical Metals Corp. (CRML) to $20, citing a strategic joint venture with a Saudi industrial group to build a rare earth processing facility. The move aims to diversify supply chains away from China and support Western defense needs.
